Cure8 research brief
This study analyzes thousands of adverse event reports for ustekinumab in Crohn’s disease and highlights infections plus possible cardiovascular and neuropsychiatric signals that clinicians and patients may want to monitor. Because the data come from FAERS, the report can generate hypotheses but cannot prove causation.
Adult patients with Crohn's disease on ustekinumab, clinicians prescribing biologics, pharmacovigilance researchers, and patients-on-biologics monitoring safety.
This paper reports a pharmacovigilance analysis of FAERS (2004‑Q1 to 2025‑Q2) examining adverse event reports linked to ustekinumab in Crohn’s disease. The authors used disproportionality methods (reporting odds ratio and proportional reporting ratio) and identified infections (lower respiratory tract infection, C.
difficile, abscess) as prominent signals and additional cardiovascular and neuropsychiatric signals. They note limitations of FAERS, including underreporting and inability to establish causality. The study is grounded in the source abstract rather than a full independent clinical review.
The findings describe reported associations in a large adverse-event database and do not prove that ustekinumab causes the listed events. The authors recommend early and continued monitoring, especially in higher-risk patients.
If you take ustekinumab or care for someone who does, this analysis highlights AE categories that regulators and researchers may watch for; it does not mean these events are common or confirmed as drug effects. Discuss any new symptoms or concerns with your clinician rather than changing treatment based on this database study alone.
FAERS is useful for signal detection but has limits (voluntary reporting, underreporting, reporting bias, lack of denominator and causality). The article is an abstract-based pharmacovigilance analysis; its signals need confirmation in controlled studies or well‑designed observational cohorts.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
For people with moderate–severe Crohn’s disease who failed anti‑TNF drugs, this trial suggests risankizumab may achieve higher corticosteroid‑free clinical and endoscopic remission than ustekinumab, which could mean...
This study reports real-world effectiveness of risankizumab for refractory Crohn's disease, showing many patients achieved steroid-free remission. The results are relevant for people weighing treatment options after...
This study provides real-world data on how well ustekinumab is kept on treatment and its safety in an Arab IBD population—information that can help patients and clinicians understand longer-term use outside clinical...
